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AbstrACt
Introduction Tourette syndrome and chronic tic disorder 
are common, disabling childhood-onset conditions. 
Guidelines recommend that behavioural therapy should 
be offered as first-line treatment for children with tics. 
However, there are very few trained behaviour therapists 
for tics and many patients cannot access appropriate 
care. This trial investigates whether an internet-delivered 
intervention for tics can reduce severity of symptoms.
Methods and analysis This parallel-group, single-blind, 
randomised controlled superiority trial with an internal 
pilot will recruit children and young people (aged 9–17 
years) with tic disorders. Participants will be randomised 
to receive 10 weeks of either online, remotely delivered, 
therapist-supported exposure response prevention 
behavioural therapy for tics, or online, remotely delivered, 
therapist-supported education about tics and co-occurring 
conditions. Participants will be followed up mid-treatment, 
and 3, 6, 12 and 18 months post randomisation. The 
primary outcome is reduction in tic severity as measured 
on the Yale Global Tic Severity Scale total tic severity 
score. Secondary outcomes include a cost-effectiveness 
analysis and estimate of the longer-term impact on 
patient outcomes and healthcare services. An integrated 
process evaluation will analyse quantitative and qualitative 
data in order to fully explore the implementation of 
the intervention and identify barriers and facilitators to 
implementation. The trial is funded by the National Institute 
of Health Research (NIHR), Health Technology Assessment 
(16/19/02).
Ethics and dissemination The findings from the study 
will inform clinicians, healthcare providers and policy 
makers about the clinical and cost-effectiveness of an 
internet delivered treatment for children and young people 
with tics. The results will be submitted for publication in 
peer-reviewed journals. The study has received ethical 
approval from North West Greater Manchester Research 
Ethics Committee (ref.: 18/NW/0079).
trial registration numbers ISRCTN70758207 and 
NCT03483493; Pre-results.
IntroduCtIon 
Tourette syndrome (TS) and chronic tic 
disorder (CTD) are common, disabling, child-
hood-onset conditions affecting up to 1% of 
strengths and limitations of this study
 ► This study is a 10-week, parallel-group, single blind, 
non-commercial, randomised controlled superiority 
trial with an internal pilot; the first large trial for in-
ternet-delivered therapy for tics in the UK.
 ► The study design and methodology are based on 
an initial pilot study of internet-delivered exposure 
response prevention for tics conducted in Sweden.
 ► The protocol was created with a multidisciplinary 
team of experts including, healthcare professionals, 
patient and public involvement members, and health 
service researchers.
 ► This trial is only available to English-speaking par-
ticipants with access to a computer/internet.
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young people and are associated with significant distress, 
psychosocial impairment and reduced quality of life.1 
The majority of patients additionally experience comor-
bidities such as attention-deficit hyperactivity disorder 
(ADHD), obsessive-compulsive disorder (OCD), depres-
sion, anxiety and self-injurious behaviour.2 Evidence-
based interventions for the treatment of tics in children 
and adolescents with TS include pharmacological treat-
ment and behaviour therapy.1 3–5 European clinical guide-
lines3 and a National Institute of Health Research Health 
Technology Assessment Evidence Synthesis1 recommend 
that behaviour therapy should be offered as a first-line 
intervention for tics in children and adolescents in a 
stepped-care approach.
Despite these recommendations, only one in five young 
people with TS are currently able to access behaviour 
therapy for tics, while around 50% receive medication,6 
which is associated with a significant risk of adverse effects 
including weight gain and sedation.4 5 Furthermore, 
those young people who manage to access behaviour 
therapy typically receive four or fewer face-to-face therapy 
sessions,6 less than half the number recommended.7 
Commonly used behaviour therapies include habit reversal 
training (HRT), whereby patients are taught to imple-
ment and maintain an action referred to as a ‘competing 
response’ when a premonitory urge to tic is experienced 
(the urge to tic often felt before the tic is expressed); 
comprehensive behavioural intervention for tics (CBIT), which 
includes HRT and adds additional elements of relaxation 
training, functional analyses (identification of situations 
which could exacerbate tics) and social support; and expo-
sure and response prevention (ERP), where patients tolerate 
premonitory urge sensations and learn from their thera-
pist how to resist their tics.
The effectiveness of behavioural therapy for reducing 
tics has been well established,1 with systematic reviews 
demonstrating a similar magnitude of effect for HRT/
CBIT compared with pharmaceutical interventions.1 4 A 
recent trial compared 10 weeks of behavioural therapy 
(either HRT or ERP) with education and pharmaco-
logical treatment and found the behavioural therapy 
to be as effective as pharmacological treatment for 
reducing tic severity, with both being superior to educa-
tion.8 Additionally, although there is a lack of evidence 
from randomised controlled trials (RCTs) for ERP, the 
evidence from available studies suggests both HRT and 
ERP may be at least equally effective in reducing tics, 
with some evidence showing a tendency to favour ERP.3 
The effectiveness of these behavioural interventions 
in conjunction with the lack of side effects compared 
with pharmacotherapy supports the use of behaviour 
therapy as a first-line intervention. However, there is a 
lack of trained therapists across many European coun-
tries, leaving many patients unable to access evidence-
based behaviour therapy. This need for improved access 
to therapy was highlighted in a recent study whereby 
families of children with TS noted the struggle to access 
limited behavioural therapy resources, despite 76% of 
parents saying they would want behavioural therapy to 
be available for their child.6
Over the last decade, internet-delivered cognitive-be-
havioural therapy (ICBT) has developed, enabling the 
delivery of effective, but less therapist intensive, cogni-
tive and behavioural interventions remotely, which can 
increase the availability of evidence-based treatments. 
Across diagnostic conditions, studies have not only shown 
efficacy of ICBT compared with no-treatment control 
conditions, but meta-analyses comparing face-to-face 
delivered CBT with ICBT have demonstrated comparable 
results in terms of symptom reduction for adults with 
mental health problems,9 10 which could also result in 
50% cost savings.10 However, therapist guidance during 
ICBT has been shown to be an important contributing 
factor in determining outcome.11 Although self-guided 
ICBT is superficially attractive, given the very low costs 
of implementation, research evidence demonstrates very 
low adherence rates.12 13
Recently, researchers at the Karolinska Institutet, 
Sweden, have developed a technical platform for ICBT 
called BIP (Barninternetprojektet, Swedish for Child Internet 
Project; http://www. bup. se/ bip). The platform has been 
used to deliver therapist-supported ICBT for a range 
of different conditions, including phobia,14 anxiety15 
and OCD.16 The findings support the use of thera-
pist-guided ICBT using the BIP system; however, there is 
little research evidence with regards to the effectiveness 
of ICBT and TS. In a recent systematic review of digital 
health interventions, Hollis and colleagues17 found the 
majority of interventions have been designed to help chil-
dren and young people at risk for developing, or with a 
diagnosis of, an anxiety disorder and/or depression, with 
areas such as TS being largely overlooked. Innovations in 
behavioural therapies for tics include delivery of CBIT 
treatment remotely via video over the internet with a 
therapist. Two pilot RCTs have compared CBIT delivered 
remotely via videoconference to traditional face-to-face 
delivery in children with TS. Results showed significant 
tic reduction for both groups, with no difference between 
the modes of delivery.18 19 The method of delivering CBIT 
was rated as highly acceptable by the participants.18
One Swedish pilot study, on which this current trial is 
based, has used the BIP platform to deliver ICBT with 
remote therapist support. The study compared tic reduc-
tion in children aged 8–16 years randomised to receive 
either ERP or HRT delivered online via the BIP plat-
form.20 Participants in both groups showed improvement 
after treatment completion, but only participants in the 
ERP arm showed significant reduction on the primary 
outcome measure Yale Global Tic Severity Scale (YGTSS) 
total tic severity score. The gains were maintained for at 
least 12 months after the end of treatment. Although this 
study was not designed or powered as a definitive efficacy 
trial, these findings show that ERP treatment delivered 
online via BIP is acceptable to participants and shows 
promise in reducing tics. Furthermore, the study reported 
no severe adverse events. There were no drop-outs and no 
 o
n
 7 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027583 on 3 January 2019. Downloaded from 
3Hall CL, et al. BMJ Open 2019;9:e027583. doi:10.1136/bmjopen-2018-027583
Open access
data loss for the primary outcome, and 83% of parents 
and children rated the treatment as good or very good, 
indicating the trial was highly acceptable to patients in 
Sweden.
However, the evidence available for the BIP treatment 
programmes has all been gathered in Sweden and we 
have limited experience of delivering therapist supported 
online ERP to children and adolescents in the UK. There 
is evidence that uptake and use of digital health interven-
tions is highly context dependent,21 22 and it would there-
fore be unwise to assume that a delivery package that 
works in Sweden will work equally well in the UK.
The overarching aim of the Online Remote Behavioural 
Intervention for Tics (ORBIT) trial is to evaluate the clin-
ical and cost-effectiveness of BIP TIC, a therapist-guided, 
parent-assisted ERP programme for tics in young people 
with TS in the UK.
Specific objectives are to
1. Optimise the design and delivery of BIP TIC in part-
nership with young people with TS, carers and health-
care professionals (HCPs) to maximise acceptability, 
effectiveness and long-term uptake.
2. Undertake an internal pilot to assess whether recruit-
ment, engagement with the intervention and reten-
tion to the trial outcomes are sufficient to allow the 
trial to progress and provide a definitive answer on ef-
fectiveness.
3. Determine the clinical effectiveness of BIP TIC com-
pared with online tic-related education in reducing 
tics, as measured by the masked assessor-rated YGTSS 
total tic severity score (primary outcome).
4. Evaluate the cost-effectiveness of BIP TIC.
5. Estimate the longer-term impact on patient outcomes 
and health service costs.
6. Conduct a process analysis in line with Medical 
Research Council (MRC) guidelines for complex in-
terventions to determine barriers and facilitators to 
implementation.
The primary hypothesis is that the BIP TIC thera-
pist-guided remote digital ERP intervention will be supe-
rior to a comparator intervention of therapist-guided 
online tic-related education in reducing tics, as meas-
ured by the masked assessor-rated YGTSS total tic severity 
score.23
MEthods And AnAlysIs
trial design
The design is a 10-week, parallel-group, single-blind, 
non-commercial, randomised controlled superiority trial 
with an internal pilot. Participants will be randomised 
to receive 10 weeks of online, remotely delivered, ther-
apist-supported ERP for tics, or online, remotely deliv-
ered, therapist-supported education for tics. Participants 
will be followed up mid-treatment, and at 3, 6, 12 and 
18 months post randomisation. Up until the 6-month 
follow-up participants are encouraged not to change 
medication or start alternative therapies for tics. Months 
12 and 18 are naturalistic follow-up points where partici-
pants are free to access any treatments in accordance with 
standard practice recommended by their usual treating 
clinician. A subsample of participants and parents will be 
purposively selected to participate in process evaluation 
interviews after the 3-month follow-up. Interviews will 
also be conducted with therapists, clinicians recruiting to 
the study and commissioners. The process evaluation will 
also link data on usage of the intervention with outcomes. 
A schematic diagram of the study design is shown in 
figure 1, and a more detailed participant flow is shown 
in figure 2.
An internal pilot will be conducted until the end of the 
ninth month to determine whether recruitment, engage-
ment with the intervention and retention to the trial are 
sufficient to allow the trial to progress, the stop/go rules 
for proceeding are
1. The study needs to have recruited 30% of the sample 
(66 participants).
2. At least 60% of participants need to have completed 
the intervention (defined as the child/adolescent 
completing at least their first four chapters).
3. 80% of participants who have reached the relevant 
time window need to have completed the primary out-
come measure.
The trial was prospectively registered with 
ISRTCN (ISRCTN70758207) and  ClinicalTrials. gov 
(NCT03483493).
setting
The intervention will be remotely delivered from two 
national centres for treating tics in the UK (Queen’s 
Medical Centre, Nottingham, and Great Ormond Street 
Hospital, London), serving geographically and demo-
graphically diverse populations. However, multiple 
Patient Identification Centres (PICs) will be involved in 
recruiting participants into the two research sites.
recruitment and eligibility
Participant identification
Participants will be identified and recruited by either (1) 
clinic staff or clinical study officers at PICs across National 
Health Services (NHS) Trusts in England; or (2) the two 
study sites (Nottingham and London) or (3) via Tourettes 
Action (tic disorder charity) website, our study website or 
social media, based on the following criteria:
Inclusion criteria
1. Aged 9–17 years.
2. Suspected or confirmed TS or chronic tic disorder.
 – Including moderate/severe tics: Total Tic Severity 
Score >15 on the YGTSS; TTSS score >10 if motor 
or vocal tics only.
3. Competent to provide written, informed consent (pa-
rental consent for child aged <16 years).
4. Broadband internet access and regular PC/laptop/
Mac user, with mobile phone SMS.
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Exclusion criteria
1. Receipt of/engaged in structured behavioural inter-
vention for tics (eg, HRT/CBIT or ERP) within the last 
12 months.
2. Change to medication for tics (start or stop) within the 
previous two months.
3. Diagnoses of alcohol/substance dependence, psycho-
sis, suicidality or anorexia nervosa.
4. Moderate/severe intellectual disability.
5. Immediate risk to self or others.
6. Parent or child not able to speak or read/write English.
Patients will be provided with a brief information sheet 
and a ‘consent to contact’ (C2C) form: for NHS-referred 
patients, these forms will be given by a member of the 
usual care team (or CSO); for self-recruited patients, 
these will be completed online.
Initial screening
On receipt of a C2C, a member of the research team 
will undertake a telephone screening interview with the 
potential participant to determine basic eligibility. Poten-
tial participants who meet the initial eligibility require-
ments will be invited to attend a face-to-face screening/
baseline appointment held at one of the two study sites. 
All participants will be reimbursed for their travel costs to 
attend this appointment.
Before participants attend the face-to-face screening/
baseline appointment parents will be asked to complete 
an online parent and teacher Development and Well-
being Assessment (DAWBA)24 (see secondary outcomes 
for further details). Completion of the parent DAWBA is 
a requirement for enrolment into the trial; findings from 
the DAWBA will be used to exclude people who score 
highly on self-harm, psychosis, anorexia nervosa or suicid-
ality. It is the parent’s decision to involve the teacher in 
completing the teacher DAWBA.
Face-to-face screening appointment
Potential participants found eligible from the initial 
telephone screening will be invited to the face-to-face 
screening/baseline appointment. Consent will be taken 
at this appointment by a researcher/assessor trained 
in Good Clinical Practice (GCP), further details about 
which are listed under ‘ethics and dissemination’. Partic-
ipants will be provided with information sheets which 
have been developed with our patient and public involve-
ment (PPI) group. Families will be encouraged to ask the 
research team any questions. Where the participant is a 
child (under 16 years), an age-appropriate participant 
information sheet will be provided.
A trained assessor will conduct the YGTSS23 assessment 
to determine the presence of tics (inclusion criteria) and 
Figure 1 Schematic flow diagram of trial design. CAIDS-Q, Child and Adolescent Intellectual Disability Screening 
Questionnaire; CTU, Clinical Trials Unit; DAWBA, Development and Wellbeing Assessment; YGTSS, Yale Global Tic Severity 
Scale.
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the Child and Adolescent Intellectual Disability Screening 
Questionnaire (CAIDS-Q)25 to screen for intellectual 
disability (exclusion criteria). Details of the YGTSS are 
described under the primary outcome.
Patients who are not eligible because they have recently 
changed their tic medication (within 2 months), or 
received a behavioural therapy for tics within the speci-
fied exclusion time frame (12 months), may be eligible 
Figure 2 Participant flow chart. Note: The CSRI includes a measure of school attendance. The YGTSS includes both a 
measure of severity and impairment. C&A-GTS-QOL, Child and adolescent version of the Gilles de la Tourette Syndrome 
Quality of Life Scale; CAIDS-Q, Child and Adolescent Intellectual Disability Screening Questionnaire; CGAS, Children’s Global 
Assessment Scale; CGI-I, Clinical Global Impressions-Improvement; CHU9D, Child Health Utility 9D; CSRI, Client Service 
Receipt Inventory; DAWBA, Development and Wellbeing Assessment; MFQ, Mood and Feelings Questionnaire; PTQ, Parent 
Tic Questionnaire; PUTS, Premonitory Urge for Tics Scale; RT, research team; SCAS, Spence Child Anxiety Scale; SCQ, Social 
Communication Questionnaire; SNAP-IV, Swanson, Nolan and Pelham Rating Scale; SDQ, Strengths and Difficulties 
Questionnaire; YGTSS, Yale Global Tic Severity Scale.
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for re-screening at a later date when these time exclusions 
have passed. Patients who meet the eligibility criteria, after 
completion of all screening assessments, will be asked to 
complete baseline measures and will be introduced to the 
BIP system.
Interventions
The BIP treatment programmes are delivered via a secure 
internet platform that enables presentation of different 
treatment content to different patient populations. 
Patients log in via personal user names and passwords 
to access the treatment content which usually includes 
text, pictures, instructional videos and worksheets (see 
link for video of the intervention https:// vimeo. com/ 
294763841/ 628b99ddfb). The treatment content for 
both groups is presented in chapters, like a self-help book.
Both the ERP (intervention) and the education (active 
control) are delivered via the BIP platform. The interven-
tions consist of 10 separate child-chapters and parent/
carer-chapters which are designed to be delivered over 10 
weeks, with access to therapist support during this time.
The child/young person and their parent/carer are 
provided with their own separate login to the BIP plat-
form to access the relevant child or parent/carer chap-
ters. The first four chapters cover the main content of 
the treatment; completion of these four child chapters is 
a minimum requirement to meet treatment completion 
criteria.
Both children and parents/carers have regular contact 
with a therapist during the 10 weeks via messages that 
can be sent inside the treatment platform (resembling 
an email) or telephone if needed. The therapist can also 
directly comment on exercises that the participant has 
been working on, and give specific feedback to motivate 
the patient. The participant typically has contact with the 
therapist several times a week, although the contact is 
asynchronous. The therapist is available to support the 
participants during these 10 weeks, although support may 
be delivered over a 12 week period if necessary to allow 
for breaks during holiday and festive periods. Access to 
the BIP treatment programme is granted for 1 year after 
the 10 weeks of therapist-guided treatment, with the 
remaining access to the BIP platform being unsupported. 
The therapist manuals for both interventions were written 
by the co-applicants.
therapist-guided, internet-delivered ErP Intervention (bIP 
tIC; experimental group)
The treatment consists of evidence-based interventions 
adapted from previously published treatment manuals 
on ERP and established behavioural intervention for 
tics protocols.26 27 During the treatment, participants are 
instructed to practice suppressing their tics: this is known 
as ‘response prevention’. Then, with the help of their 
parent/carer, the participant is instructed to provoke 
premonitory urges and control all of their tics: this is 
known as ‘exposure’. Through treatment, the child gains 
mastery in tolerating the urge, controlling the tics and 
is able to do so for increasingly longer periods of time. 
The participants also receive detailed education about 
tics and strategies to promote tic management at school.
The parent modules contain information regarding 
parent coping strategies, how to support their child in 
working with BIP and functional analysis relating to tics.
therapist-guided, internet-delivered education (active control 
group)
An active comparator intervention was chosen to ensure 
that all participants still received an internet-delivered 
therapist-guided intervention over and above what would 
typically be received in standard care. Education about 
tics (without a specific focus on training behavioural strat-
egies to reduce tics) was chosen to enable a comparison to 
previous trials of face-to-face behaviour therapy for tics.28
The comparator intervention was developed for the 
trial and consisted of educational information about TS 
and co-occurring conditions. The material was adapted 
and updated from the educational intervention used in 
two previous RCTs.26 28
The chapters have been matched in length to that of the 
behavioural intervention. The comparator intervention 
reviews the definition of tics, natural history, common 
presentations, prevalence, aetiology, risks and protective 
factors and strategies for describing tics to other people, 
and so on. Problem-solving and development of exper-
tise in tic disorders is emphasised. The parent modules 
emphasise parent coping strategies and self-care in caring 
for a child with tic disorder. There is no information on 
tic control within the comparator intervention.
start of treatment
The participant will agree a start date for commencing 
therapy with their assessor at the screening/baseline 
appointment (typically within 24–48 hours of the baseline 
appointment). The participant will be reminded that it 
is important to log-on and start the therapy on the allo-
cated date. At the start, the therapist will release the first 
two chapters of the intervention for the participants to 
complete and monitor their progress, sending reminders 
and feedback where necessary. If the participant does not 
start the intervention at the agreed start time, the 10-week 
start date does not alter.
All therapists will undergo training delivered by a 
supervisor (TM or JK) before commencing either inter-
vention. Therapists will be closely supervised by TM or 
JK to ensure adherence to protocol. The team from 
the Karolinska Institutet will provide technical support 
throughout the trial.
Measures and outcomes
Primary outcome
The primary outcome is the severity of tics as measured by 
the TTSS (0–50) on the YGTSS.23 The primary end point 
is 3 months post randomisation. The TTSS combines 
separate scales for motor tics (0–25) and for vocal tics 
(0–25). The primary outcome measure (TTSS) will be 
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measured at baseline (pre-intervention), 3 months, 6, 12 
and 18 months post randomisation.
The YGTSS is administered by a blinded assessor as 
an investigator-based semistructured interview focusing 
on motor and vocal tic frequency, severity and tic-re-
lated impairment over the previous week. The baseline 
assessment will be conducted face-to-face at the baseline/
screening appointment. When possible, the follow-up 
assessments will be conducted by the same blinded 
assessor that conducted the baseline assessment via video-
conference call/WebEx or telephone. With the partici-
pants’ permission, all YGTSS assessments will be recorded 
for quality checks.
All assessors/researchers will be trained in conducting 
YGTSS by a clinical expert (TM). Agreement with the 
expert rater will be established at the start of the trial and 
monitored every 6 months. Assessors have to be within 
15% of the expert rater (TM) for the Total Motor Tic 
score, the Total Vocal Tic score and the Total Tic Score on 
three YGTSS recordings at baseline and four randomly 
selected recordings at follow-up. Assessors who do not 
meet this threshold of agreement will be re-trained.
Secondary outcomes
A flow chart of study assessments is shown in table 1 which 
documents the time point for completion and the infor-
mant. See also figure 2.
 ► YGTSS: impairment scale23: The impairment scale 
(0–50) forms part of the YGTSS described above. 
The rating focuses on distress and impairment expe-
rienced in interpersonal, academic and occupational 
domains.
 ► Parent Tic Questionnaire (PTQ)29: The PTQ assesses the 
number, frequency and intensity of motor and vocal 
tics.
 ► Clinical Global Impressions Scale (CGI) improvement30: The 
CGI improvement provides an overall clinician-deter-
mined summary measure of symptom improvement.
 ► Children’s Global Assessment Scale (CGAS)31: The CGAS 
is a 0–100 scale that integrates psychological, social 
and academic functioning in children as a measure of 
psychiatric disturbance.
 ► Strengths and Difficulties Questionnaire (SDQ—parent 
completed)32: The SDQ is a brief measure of behav-
ioural and emotional difficulties. The SDQ will be 
completed by parents as part of DAWBA at baseline 
and at follow-up via an online platform.
 ► The Mood and Feelings Questionnaire (MFQ; Child 
completed version)33: The MFQ reports depressive symp-
toms as specified by the DSM-III-R diagnostic criteria 
for major depression.
 ► Spence Child Anxiety Scale (SCAS—self-report)34: The 
SCAS is a self-report measure that evaluates symptoms 
relating to separation anxiety, social phobia, OCD, 
pain, agoraphobia, generalised anxiety and fears of 
physical injury.
 ► Child Health Utility 9D (CHU9D; parent and child 
completed versions)35: The CHU9D is a paediatric quality 
of life measure for use in healthcare resource-alloca-
tion decision making.
 ► The Child and Adolescent Gilles de la Tourette Syndrome—
Quality of Life Scale (C&A-GTS-QOL)36: The 
C&A-GTS-QOL is a disease-specific measure of 
health-related quality of life designed for children 
and adolescents with TS.
 ► Client Service Receipt Interview (CSRI)37: The CSRI is a 
flexible research instrument developed to collect 
information on service receipt, service-related issues 
and income. A modified version of the CSRI will be 
completed which also combines elements of the Child 
and Adolescent Service Use Schedule (CA-SUS).38
 ► Adverse events (side effects): Adverse events/side effects 
will be recorded on a modified version of the side 
effects scale developed by Hill and Taylor.39
The abovementioned scales all have established relia-
bility, validity and history of use in clinical and research 
settings. Some further measures were developed by the 
research team for the purpose of this study; these include
 ► Treatment credibility: The questionnaire consists of 
two items which ask how suitable the child and parent 
believe the internet treatment is for managing tics, 
and how much improvement they expect from the 
treatment.
 ► Treatment satisfaction and need for further treatment: 
Seven items ask about the child’s/parent’s satisfaction 
with the treatment and an additional question asks 
whether they feel more tic treatment is required.
 ► Concomitant interventions: To assess what other treat-
ments/interventions the child/young person is 
accessing during the study period, parents will be 
asked to complete a short questionnaire docu-
menting other interventions (including medication) 
in progress.
Additional baseline measures
To further characterise the sample at baseline, the 
following measures will also be recorded:
 ► Demographics questionnaire: Records the child’s age, 
gender, ethnicity, parental education/occupation, 
list of the child’s current diagnoses and interventions 
(including medications) and general practitioner 
(GP) and school details.
 ► Social Communication Questionnaire (SCQ)40: The SCQ is 
a screening tool for autism spectrum disorder (ASD).
 ► Premonitory Urge for Tics Scale (PUTS)41: The PUTS is 
a self-report instrument that measures premonitory 
urges in tic disorders.
 ► Swanson, Nolan, and Pelham Rating Scale (SNAP-IV)42: 
The SNAP-IV is a behavioural rating scale that includes 
the core symptoms of ADHD and oppositional-defiant 
disorder (ODD).
Process evaluation
The process evaluation will follow the MRC guidelines 
for evaluating the implementation of complex interven-
tions.43 44 It will explore the fidelity and implementation 
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of intervention, and make recommendations for adap-
tations. It will also examine the potential mechanisms 
underlying participant behaviour change and probe for 
unexpected consequences.
Interviews will be conducted with therapists and their 
supervisors supporting the intervention (target n>5), 
clinicians recruiting to the study (n >10), children (n>20 
in each arm) and parents of children in both arms (n>20 
in each arm). Online feedback from participants will also 
be analysed together with indices recorded as part of the 
BIP system such as total therapist time, number of chap-
ters clicked through and number of patient log-ins.
Patient and public involvement
A group of PPI members was created to shape and guide 
the study. The group comprises four parents and four chil-
dren and young people with a diagnosis of TS, plus two 
PPI members with previous experience of large studies. 
The design of the trial and its dissemination will also have 
been shaped by PPI in the following ways:
 ► Reviewing and selection of outcome measures.
 ► Co-developing of study materials and recruitment 
processes.
 ► Reviewing the interventions and providing feedback 
on all chapters.
 ► Attending ongoing trial team meetings to provide 
PPI perspective and assist with troubleshooting (eg, 
recruitment and retention).
 ► Guiding interview topics and shaping questions for 
process evaluation.
 ► Co-creating lay summaries and other dissemination 
materials.
The PPI group mainly contributes remotely, in order to 
enable involvement from members who are not geograph-
ically close. Face-to-face input occurs at key points, for 
example, attendance at trial team meetings.
Sample size
To detect a clinically important average difference of 
0.5, of an SD between intervention and comparator with 
90% power at p<0.05 (two-sided), after allowing for 20% 
dropout, requires a total sample size of 220 participants. 
A systematic review found the average estimate for the SD 
of the YGTSS (TTSS) from 19 trials of behavioural inter-
vention for tics was 6.6.17 Thus, the trial is powered to 
detect an average difference of 3.3 on the YGTSS.
Recruitment is planned to be conducted within 
an 18-month period. We are not aware of any other 
competing studies that are in progress or planned that 
would affect recruitment. Input received from young 
people and carers in developing this trial indicates that 
participation in the trial will be attractive as it guaran-
tees access to an intervention. Our national recruitment 
network of specialist (PIC) clinics, including multiple 
community child and adolescent mental health services 
and paediatric clinics and the charity Tourettes Action, 
have the capacity to meet the recruitment target within 
the time window. Recruitment figures will be monitored 
monthly by the trial manager (CLH) and any shortfall will 
be reported to the project management group (PMG).
Randomisation
Randomisation will be conducted using the Sealed 
Envelope online randomisation system and managed 
by Priment Clinical Trials Unit. Participants will be 
randomised online by the researcher/assessor. Randomi-
sations will be distributed equally between the two arms 
(ratio 1:1) and stratified by study site using block rando-
misation with varying block sizes. The researcher will 
remain blind to the treatment allocation, and the ther-
apist will be notified of the treatment allocation. Thera-
pists will set up participants’ treatment on the BIP system.
All participants receive the same outcome measures 
so assessors will not know which group the partici-
pant is in by the measurements. If an assessor becomes 
unblinded, subsequent assessments for that participant 
will be conducted by a different assessor (blind to arm 
allocation) where possible. In case of a medical emer-
gency, participants will be able to disclose to the treating 
physician (eg, GP) what treatment they received without 
unblinding the researchers. Outcome assessors will guess 
the treatment allocation after each assessment, to be able 
to calculate if the guesses are better than random.
Data management and analysis
Participants who do not complete therapy or measures 
at a given time point will still be followed up until the 
end of the trial unless they inform the research team they 
would like to withdraw from the trial. Participants will be 
reimbursed with £20 vouchers for completing measures 
at baseline and each follow-up time point, except the 
mid-treatment follow-ups (3 and 5 weeks).
All aspects of data management of the study will comply 
with the UK Data Protection Act 1998/General Data 
Protection Regulation, Priment’s standard operating 
procedures and GCP. Outcome measures will be stored in 
BASS, a rating platform stored on a Swedish server. Partic-
ipant-completed outcome measures are directly entered 
into an online database by the participant. Assessor/
researcher-completed measures may initially be entered 
on a paper case report form or directly into the database. 
Data extraction will be performed within the UK.
Statistical analysis
All baseline variables will be summarised by randomised 
group. Categorical data will be reported as frequencies 
(%) and continuous data will be reported as mean (SD) 
unless skewed then they will be reported as median 
(IQR). No statistical tests will be carried out comparing 
baseline variables. The primary outcome (TTSS of the 
YGTSS at 3 months post-randomisation) will be analysed 
using a linear regression model, including baseline TTSS 
and centre (the stratification variable). If the assumptions 
of linear regression are violated, another suitable method 
will be used. Primary analyses will be performed using 
intention-to-treat principles. Predictors of missingness 
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will be examined. If any are found, they will be included 
in statistical models in a supportive analysis. There are no 
planned subgroup analyses.
Secondary outcomes will be analysed using similar 
statistical methods as the primary outcome. Continuous 
outcomes will be analysed with linear regression. Dichoto-
mous outcomes will be analysed using logistic regression. 
Results will be presented as estimated differences or ORs 
as appropriate, with accompanying 95% CI. P values will 
not be reported for secondary outcomes.
Economic analysis
The primary cost-effectiveness analysis for the within-trial 
evaluation will be the mean incremental cost per point 
change in YGTSS of treatment as usual (TAU) plus BIP 
TIC compared with TAU plus online education with ther-
apist support at 3 months, from an NHS and personal 
social services cost perspective.
A secondary analysis of the mean incremental cost 
per quality-adjusted life-year (QALY) of the intervention 
compared with the active control from a health and social 
care cost perspective will also be calculated. A decision 
model projecting costs and QALYs into adulthood will 
also be developed.
Qualitative analysis
Interview data collected from the process evaluation will 
be analysed using thematic analysis.45 Data will be anal-
ysed using NVivo to establish themes and subthemes. A 
mixed-methods approach will be used to integrate quanti-
tative and qualitative data in order to fully explore imple-
mentation of the intervention.
Monitoring
Management and oversight
There are three committees in place to oversee the trial, 
including a PMG, Trial Steering Committee (TSC) and 
Data Monitoring and Ethics Committee (DMEC). The 
PMG consists of all the co-investigators listed on the 
protocol who will meet at least every six months to discuss 
the study progress and overall conduct of the trial. The 
role of the TSC will be to provide overall supervision for 
the trial on behalf of the Trial Sponsor and Trial Funder, 
to ensure that the trial is conducted in accordance with 
GCP and to review the findings of the internal pilot. 
The DMEC is the only body involved in the trial that has 
access to the unblinded comparative data. The role of its 
members is to monitor these data and make recommen-
dations to the TSC on whether there any ethical or safety 
reasons why the trial should not continue. There are no 
interim analyses planned; however, this does not preclude 
the DMEC from requesting analyses. The TSC and DMEC 
will meet annually. The charters are available on request 
from the corresponding author.
Adverse events
There are no anticipated serious adverse events. All 
adverse events will be recorded and monitored, and 
the chief investigator and medical expert (CH) will 
determine seriousness and causality and report the event 
to the DMEC and ethics committee where necessary. Side 
effects will be formally monitored via completion of the 
side-effects scale throughout the intervention and for 
3 months after the intervention finishes (month 6).
Audit
The trial manager, or a nominated designee of the 
sponsor, shall carry out monitoring of trial data as an 
ongoing activity. The sponsor may decide to carry out a 
full audit of the trial and the trial management systems/
procedures in the event of serious breaches to GCP or 
protocol. Trial data and evidence of monitoring and 
system audits will be made available for inspection by the 
Research Ethics Committee as required.
EthICs And dIssEMInAtIon
The study received ethical and Health Research Authority 
(HRA) approval from North West Greater Manchester 
Research Ethics Committee on 23 March 2018 (ref.: 
18/NW/0079: protocol V.2.0, 26 February 2018). Local 
approvals have been granted from the participating 
Trusts. The study is sponsored by Nottinghamshire 
Healthcare NHS Foundation Trust; neither the sponsor 
nor the funders will be involved in the analysis of study 
data or report writing. Only the UK research team will 
have access to the study data, which will be stored in 
secure locked files or password protected databases. Data 
will be available for inspection by the ethics committee on 
request. Changes to the protocol will be communicated to 
the ethics committee, funders, and trial registries by the 
trial manager (CLH). The process for obtaining partic-
ipant informed consent or assent and parent/guardian 
informed consent will be in accordance with the ethical 
guidance and GCP. The investigator or their nominee 
and the participant or other legally authorised represen-
tative (such as the child’s parent) shall both sign and date 
informed consent forms before the person can partic-
ipate in the study. Where the young person is 16 years 
and over, written consent will be required from both the 
parent (online supplementary file A) and young person 
(online supplementary file B). Where the young person is 
under 16 years, written parental consent will be required, 
alongside the young person’s assent (supplementary file 
C). In the event of any conflict between the parent and 
child, the child will not enter the study.
Individual participant medical information obtained as 
a result of this study is considered confidential and disclo-
sure to third parties is prohibited unless warranted by an 
adverse event. Participant confidentiality will be further 
ensured by utilising identification numbers to correspond 
to treatment data in the computer files. No post-trial 
care is required; however, participants will have access to 
the intervention for 1 year after starting the treatment, 
although this access will be without therapist support after 
the 10/12 weeks. The chief investigator and site principal 
investigators declare no financial or competing interests. 
 o
n
 7 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027583 on 3 January 2019. Downloaded from 
11Hall CL, et al. BMJ Open 2019;9:e027583. doi:10.1136/bmjopen-2018-027583
Open access
At the end of the trial, the data belongs to the chief inves-
tigator and the study sponsor. All members of the team 
will have access to the final trial data set. The findings 
will be published in peer-reviewed journals, presented at 
relevant conferences and disseminated to the public via 
lay summaries co-created with our PPI group. All outputs 
will be authored by the research team and will not involve 
professional writers. Access to the full protocol is available 
on request to the corresponding author.
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